Let My ‘Mice’ Answer… Does alternative required for animal testings?


  Not a week goes by without news of a lab breakthrough using rats or mice. But of all the promising medical interventions that make it to animal trials, only a fraction seem to translate into major breakthroughs for humans. … Continue reading

FDA approves linagliptin tablets for the treatment of type 2 diabetes!

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.(1) The FDA has approved linagliptin as a monotherapy or in combination with other commonly prescribed medications for type (2) diabetes—such as metformin, sulphonylurea and pioglitazone – to reduce haemoglobin A1c (HbA1c or A1c) levels by a mean of up to -0.7 percent (compared to placebo).(2) HbA1c is measured in people with diabetes to provide an index of blood sugar control for the previous two to three months. It is used as a marker of efficacy of antihyperglycaemic therapies.

Boehringer Ingelheim

Linagliptin belongs to a class of prescription medications called dipeptidyl peptidase-4 (DPP-4) inhibitors and is the first member of its class to be approved at one dosage strength (5 mg, once daily).(1) With linagliptin, no dose adjustment is recommended for patients with kidney or liver impairment. Linagliptin is a tablet that can be taken with or without food. Linagliptin lowers blood sugar in a glucose-dependent manner by increasing incretin levels (GLP-1), which increase insulin levels after meals and throughout the day.(1)

“Many people with type 2 diabetes are not able to control their blood sugar with diet and exercise alone and may also require one or more medications,” said John Gerich M.D., Professor of Medicine, University of Rochester School of Medicine. “The FDA approval of linagliptin is exciting because there is only Continue reading

A lecture Video… Human Teratogenecity: Preclinical Evaluation of Toxicology of Reproductive System..!

Human Teratogenecity: Preclinical Evaluation of Toxicology of Reproductive System..!

An Interesting lecture… UCSD Department of Pediatrics & the Skaggs School of Pharmacy and Pharmaceutical Sciences bring together world-renowned experts in the field of Human Teratology in a new series providing clinicians an update on the environmental causes of birth defects. In this program, Anthony Scialli, M.D., Reproductive Toxicology Center, discusses Preclinical Evaluation of Reproductive and Developmental Toxicity. Series: “Human Teratology: Environmental Causes of Birth Defects… see the video below!

Human Teratogenecity: Preclinical Evaluation of Toxicology of Reproductive System..!